TY - JOUR
T1 - Risk of subsequent primary lymphoma in a cohort of 69,460 five-year survivors of childhood and adolescent cancer in Europe
T2 - The PanCareSurFup study
AU - Dudley, Isabelle M.
AU - Sunguc, Ceren
AU - Heymer, Emma J.
AU - Winter, David L.
AU - Teepen, Jop C.
AU - Belle, Fabiën N.
AU - Bárdi, Edit
AU - Bagnasco, Francesca
AU - Gudmundsdottir, Thorgerdur
AU - Skinner, Roderick
AU - Michel, Gisela
AU - Byrne, Julianne
AU - Øfstaas, Hilde
AU - Jankovic, Momcilo
AU - Mazić, Maja Česen
AU - Mader, Luzius
AU - Loonen, Jaqueline
AU - Garwicz, Stanislaw
AU - Wiebe, Thomas
AU - Alessi, Daniela
AU - Allodji, Rodrigue S.
AU - Haddy, Nadia
AU - Grabow, Desiree
AU - Kaatsch, Peter
AU - Kaiser, Melanie
AU - Maule, Milena M.
AU - Jakab, Zsuzsanna
AU - Gunnes, Maria Winther
AU - Terenziani, Monica
AU - Zaletel, Lorna Zadravec
AU - Kuehni, Claudia E.
AU - Haupt, Riccardo
AU - de Vathaire, Florent
AU - Kremer, Leontien C.
AU - Lähteenmäki, Päivi M.
AU - Winther, Jeanette F.
AU - Hjorth, Lars
AU - Hawkins, Michael M.
AU - Reulen, Raoul C.
N1 - Publisher Copyright:
© 2022 The Authors. Cancer published by Wiley Periodicals LLC on behalf of American Cancer Society.
PY - 2022
Y1 - 2022
N2 - Background: Survivors of Hodgkin lymphoma (HL) are at risk of developing non-Hodgkin lymphoma (NHL) after treatment; however, the risks of developing subsequent primary lymphomas (SPLs), including HL and NHL, after different types of childhood cancer are unknown. The authors quantified the risk of SPLs using the largest cohort of childhood cancer survivors worldwide. Methods: The Pan-European Network for Care of Survivors After Childhood and Adolescent Cancer (PanCare) Survivor Care and Follow-Up Studies (PanCareSurFup) cohort includes 69,460 five-year survivors of childhood cancer, diagnosed during 1940 through 2008, from 12 European countries. Risks of SPLs were quantified by standardized incidence ratios (SIRs) and relative risks (RRs) using multivariable Poisson regression. Results: Overall, 140 SPLs, including 104 NHLs and 36 HLs, were identified. Survivors were at 60% increased risk of an SPL compared with the general population (SIR, 1.6; 95% confidence interval [CI], 1.4–1.9). Survivors were twice as likely to develop NHL (SIR, 2.3; 95% CI, 1.9–2.8), with the greatest risks among survivors of HL (SIR, 7.1; 95% CI, 5.1–10.0), Wilms tumor (SIR, 3.1; 95% CI, 1.7–5.7), leukemia (SIR, 2.8; 95% CI, 1.8–4.4), and bone sarcoma (SIR, 2.7; 95% CI, 1.4–5.4). Treatment with chemotherapy for any cancer doubled the RR of NHL (RR, 2.1; 95% CI, 1.2–3.9), but treatment with radiotherapy did not (RR, 1.2; 95% CI, 0.7–2.0). Survivors were at similar risk of developing a subsequent HL as the general population (SIR, 1.1; 95% CI, 0.8–1.5). Conclusions: In addition to HL, the authors show here for the first time that survivors of Wilms tumor, leukemia, and bone sarcoma are at risk of NHL. Survivors and health care professionals should be aware of the risk of NHL in these survivors and in any survivors treated with chemotherapy.
AB - Background: Survivors of Hodgkin lymphoma (HL) are at risk of developing non-Hodgkin lymphoma (NHL) after treatment; however, the risks of developing subsequent primary lymphomas (SPLs), including HL and NHL, after different types of childhood cancer are unknown. The authors quantified the risk of SPLs using the largest cohort of childhood cancer survivors worldwide. Methods: The Pan-European Network for Care of Survivors After Childhood and Adolescent Cancer (PanCare) Survivor Care and Follow-Up Studies (PanCareSurFup) cohort includes 69,460 five-year survivors of childhood cancer, diagnosed during 1940 through 2008, from 12 European countries. Risks of SPLs were quantified by standardized incidence ratios (SIRs) and relative risks (RRs) using multivariable Poisson regression. Results: Overall, 140 SPLs, including 104 NHLs and 36 HLs, were identified. Survivors were at 60% increased risk of an SPL compared with the general population (SIR, 1.6; 95% confidence interval [CI], 1.4–1.9). Survivors were twice as likely to develop NHL (SIR, 2.3; 95% CI, 1.9–2.8), with the greatest risks among survivors of HL (SIR, 7.1; 95% CI, 5.1–10.0), Wilms tumor (SIR, 3.1; 95% CI, 1.7–5.7), leukemia (SIR, 2.8; 95% CI, 1.8–4.4), and bone sarcoma (SIR, 2.7; 95% CI, 1.4–5.4). Treatment with chemotherapy for any cancer doubled the RR of NHL (RR, 2.1; 95% CI, 1.2–3.9), but treatment with radiotherapy did not (RR, 1.2; 95% CI, 0.7–2.0). Survivors were at similar risk of developing a subsequent HL as the general population (SIR, 1.1; 95% CI, 0.8–1.5). Conclusions: In addition to HL, the authors show here for the first time that survivors of Wilms tumor, leukemia, and bone sarcoma are at risk of NHL. Survivors and health care professionals should be aware of the risk of NHL in these survivors and in any survivors treated with chemotherapy.
KW - childhood cancer survivors
KW - Hodgkin lymphoma
KW - late effects
KW - non-Hodgkin lymphoma
KW - second cancers
KW - subsequent primary lymphoma
UR - http://www.scopus.com/inward/record.url?scp=85142914919&partnerID=8YFLogxK
U2 - 10.1002/cncr.34561
DO - 10.1002/cncr.34561
M3 - Article
AN - SCOPUS:85142914919
SN - 0008-543X
JO - Cancer
JF - Cancer
ER -